CAR2 Anti-CD38 A2 CAR-T Cells has the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity. CAR2 Anti-CD38 A2 CAR-T Cells are being evaluated in multiple myeloma (MM) and has successfully demonstrated strong preclinical anti-tumor activity in animal models.
| SparkCures ID | 314 |
|---|---|
| Developed By | Sorrento Therapeutics, Inc. |
| Generic Name | CAR2 Anti-CD38 A2 CAR-T Cells |
| Treatment Classifications |
|
| Treatment Targets |
Download a patient-friendly brochure to learn more about this clinical trial and the best way to connect with the Roger Williams Medical Center.